Esperion (ESPR) CEO sells shares to cover RSU taxes, retains 2.12M

Rhea-AI Filing Summary

Esperion Therapeutics, Inc. President and CEO Sheldon L. Koenig reported an open-market sale of 53,588 shares of common stock at an average price of $3.155 per share. According to the footnote, the shares were sold to satisfy tax obligations on vested restricted stock units.

After this transaction, Koenig directly holds 2,119,111 shares of Esperion common stock, indicating he retains a substantial equity stake in the company despite the sale for tax purposes.

Insights

Insider transactions analyst

CEO’s sale is tied to tax on vesting and leaves a large remaining stake.

CEO Sheldon L. Koenig sold 53,588 Esperion common shares at $3.155 per share in an open-market transaction. A footnote explains the sale was made to satisfy tax obligations arising from vested restricted stock units, which is typically a mechanistic event.

Following the sale, Koenig still holds 2,119,111 shares directly, far exceeding the amount sold. With no derivative positions listed and the sale linked to taxes, this filing points to routine compensation-related activity rather than a directional change in his exposure to Esperion Therapeutics (ESPR).

Insider Trade Summary

Net Seller: 53,588 shares

Net Sell 1 txn

Insider Koenig Sheldon L.

Role President and CEO

Sold 53,588 shs ($169K)

Type	Security	Shares	Price	Value
Sale	Common Stock	53,588	$3.155	$169K

Holdings After Transaction: Common Stock — 2,119,111 shares (Direct)

Footnotes (1)

1. F1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Key Figures

Shares sold: 53,588 shares Sale price: $3.155 per share Shares held after transaction: 2,119,111 shares +1 more

4 metrics

Shares sold 53,588 shares Open-market sale to satisfy tax on vested RSUs

Sale price $3.155 per share Price for Esperion common stock sold by CEO

Shares held after transaction 2,119,111 shares CEO’s direct Esperion common stock holdings post-sale

Transactions reported 1 sale transaction Single non-derivative open-market sale in this Form 4

Key Terms

open-market sale, restricted stock units, Form 4, insider transaction

4 terms

open-market sale financial

"The transaction was an open-market sale of 53,588 shares at $3.155 per share."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

restricted stock units financial

"Shares were sold to satisfy tax obligation on vested shares of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Form 4 regulatory

"This Form 4 reports an open-market sale of Esperion common stock by the CEO."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

insider transaction financial

"The insider transaction involves the CEO selling shares primarily to meet tax obligations."

FAQ

What did Esperion Therapeutics (ESPR) CEO Sheldon Koenig report in this Form 4?

He reported selling 53,588 common shares at $3.155 each. The transaction was an open-market sale, and a footnote states it was conducted to cover tax obligations from vested restricted stock units, rather than a discretionary portfolio rebalancing.

Why did Esperion CEO Sheldon Koenig sell 53,588 ESPR shares?

The sale was to satisfy tax obligations on vested restricted stock units. The footnote clarifies that proceeds from selling 53,588 shares were used to pay taxes triggered when restricted stock units vested, a common practice in equity compensation programs.

How many Esperion (ESPR) shares does the CEO hold after this transaction?

After the sale, Sheldon Koenig holds 2,119,111 shares. This post-transaction holding, disclosed in the Form 4, shows that his remaining direct ownership is significantly larger than the 53,588 shares sold for tax-related reasons.

Was the Esperion CEO’s Form 4 transaction a buy or a sell of ESPR stock?

The Form 4 reports a sale of Esperion common stock. It records an open-market sale of 53,588 shares at $3.155 per share, specifically described as being executed to satisfy tax liabilities tied to restricted stock unit vesting.

Does the Form 4 show any Esperion derivative or option exercises by the CEO?

No derivative transactions are listed in this Form 4. The derivative summary is empty, indicating no option or other derivative exercises in this filing; the only reported activity is the common stock sale related to RSU tax obligations.

What is the approximate scale of the Esperion CEO’s sale versus his remaining ESPR holdings?

The CEO sold 53,588 shares and retained 2,119,111 shares. This comparison, disclosed in the filing, shows the transaction reduced his position by a relatively small portion, with the sale driven by tax obligations on vested restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/18/2026 - 04:06 PM Accepted by SEC EDGAR 06/18/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Koenig Sheldon L.

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MICHIGAN 48108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		S		53,588(1)	D	$3.155	2,119,111	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)